441 related articles for article (PubMed ID: 23370314)
1. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
4. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
Crawford J; Swanson P; Schwarzenberger P; Sandler A; Prager D; Zhang K; Freeman DJ; Johnson CW; Krishnan K; Johnson D
J Thorac Oncol; 2013 Dec; 8(12):1510-8. PubMed ID: 24389433
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Socinski MA; Scappaticci FA; Samant M; Kolb MM; Kozloff MF
J Thorac Oncol; 2010 Mar; 5(3):354-60. PubMed ID: 20032789
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
[TBL] [Abstract][Full Text] [Related]
9. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
[TBL] [Abstract][Full Text] [Related]
10. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler AB; Schiller JH; Johnson DH;
J Clin Oncol; 2008 Jan; 26(1):60-5. PubMed ID: 18165641
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
12. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Cohen EE; Subramanian J; Gao F; Szeto L; Kozloff M; Faoro L; Karrison T; Salgia R; Govindan R; Vokes EE
Clin Lung Cancer; 2012 Mar; 13(2):123-8. PubMed ID: 22100149
[TBL] [Abstract][Full Text] [Related]
13. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
16. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
18. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
19. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Novello S; Scagliotti GV; Sydorenko O; Vynnychenko I; Volovat C; Schneider CP; Blackhall F; McCoy S; Hei YJ; Spigel DR
J Thorac Oncol; 2014 Aug; 9(8):1154-61. PubMed ID: 25157768
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
